title: Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Collaborative Retina Study Group.
abstract: OBJECTIVE
  To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients.
  
  
  METHODS
  Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab).
  
  
  RESULTS
  There were 24 girls and 15 boys with group median age of 13 years (range, 3-17 years). Mean follow-up period was 12.8 months (range, 3-60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation and last follow-up was 0.87 and 0.7, respectively (P = 0.0003). Mean and median number of injections received over the follow-up period was 2.2 and 1, respectively. At the last follow-up, 22 eyes (48%) gained more than 3 lines of vision and 27 eyes (60%) had final visual acuity 20/50 or better. Nine eyes (20%) did not improve and had severe vision loss (20/200 or worse).
  
  
  CONCLUSIONS
  Intravitreal antiangiogenic therapy for choroidal neovascularization in pediatric patients seems temporarily safe and effective in majority of affected eyes. Because of the rarity and character of this condition, it is unlikely that any clinical trials will soon take place to study this or other treatment option.
authors: *Ophthalmology Service, Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; †Department of Ophthalmology, Professor Albrecht Meerhoff Clinic, American University of Beirut, Beirut, Lebanon; ‡Charles Retina Institute, Memphis, Tennessee; §San Giuseppe Hospital, University Eye Clinic, Milan, Italy; ¶Department of Ophthalmology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico; **University of Valencia School of Medicine, and Department of Ophthalmology, Hospital Universitario La Fe de Valencia, Valencia, Spain; ††L. V. Prasad Eye Institute, Hyderabad, India; ‡‡Servicio de Oftalmologia, Instituto de la Vision, Hospital Universitario Austral, Buenos Aires, Argentina; §§Clinica Professor Albrecht Meerhoff, Montevideo, Uruguay; ¶¶Department of Ophthalmology and Visual Sciences, University of Chicago at Illinois, Chicago, Illinois; and ***Retina Division, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
authors: Igor
authors: I
authors: Kozak
authors: Ahmad
authors: A
authors: Mansour
authors: Rocio I
authors: RI
authors: Diaz
authors: Jorge I
authors: JI
authors: Calzada
authors: Francesco
authors: F
authors: Pichi
authors: Vanessa
authors: V
authors: Cruz-Villegas
authors: Manuel
authors: M
authors: Diaz-Llopis
authors: Roberto
authors: R
authors: Gallego-Pinazo
authors: Jay
authors: J
authors: Chhablani
authors: Mauricio
authors: M
authors: Martinez-Cartier
authors: Martin
authors: M
authors: Meerhoff
authors: William F
authors: WF
authors: Mieler
authors: J Fernando
authors: JF
authors: Arevalo
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002648:Child; D002675:Child, Preschool; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab